hotspot -WSS

hotspot

author：comprehensive 2025-09-27 12:34:38 - browse：71

Two researchers look at a projection screen displaying medical devices, scientific graphs and DNA — health tech coverage from STAT — Adobe

The federal government’s plan to boost its oversight of the use of artificial intelligence tools in health care drew censure from startups arguing that overregulation stifles new ideas. But as Washington forges ahead, founders say they’re in the dark about who will be regulated and how — and they’re urging policymakers to offer clarity.

As they race for a slice of the $4 trillion U.S. health care market, AI founders and investors say regulatory uncertainty is a hurdle, forcing them to build more slowly and meticulously document for fear of potential audits. That makes it harder to keep up with the tech industry’s breakneck pace, they tell STAT.

The regulatory uncertainty adds to the many challenges dogging young health tech ventures today: Last year investments in digital health startups shriveled to their lowest annual total since 2019, and leaders are desperate to preserve what little funds they have, including through layoffs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Prior authorization will have to move faster under new Biden rule

WSS

Readout Newsletter: Merck, J&J, and long Covid

Dewpoint Therapeutics lays off staff after losing partnerships

Elizabeth Holmes banned from government health programs

Why doctors need education on FDA device approval process

The surgeon had a dilemma only a Nazi medical text could resolve

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Food makers tried to stack nutrition panel with preferred experts

In age of alternative facts, a scholarly course on calling out crap

FDA approves updated Covid vaccines

Medical leaders decry Supreme Court decision on affirmative action

The surgeon had a dilemma only a Nazi medical text could resolve

Alkermes shareholders re

What to make of Biden’s latest efforts on cancer research

Medical leaders decry Supreme Court decision on affirmative action

Long Covid needs a new name — and a new frame

explore

AI generated plenty of interest at JPM but not a lot of trust

NIH director takes cautious approach to Biden drug pricing priority

Elizabeth Holmes banned from government health programs

The surgeon had a dilemma only a Nazi medical text could resolve

FDA clears AI tool for detecting skin cancer

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

leisure time

hotspot

explore